A Cruise Ship Outbreak Put Hantavirus in the Headlines. Three Decades of Neglect Explain Why There's Still No Vaccine.

In early April 2026, the Dutch polar cruise ship MV Hondius departed Ushuaia, Argentina, carrying roughly 150 passengers on an expedition through the South Atlantic. Within weeks, passengers began falling ill with severe respiratory distress. By May 9, eight suspected cases had been identified — six confirmed as hantavirus infection caused by the Andes virus — and three passengers were dead [1][2]. The ship, with 147 people still aboard, was en route to Tenerife as health authorities across six countries traced contacts and monitored hospitalized survivors [3].

The outbreak generated worldwide alarm. WHO Epidemic and Pandemic Preparedness chief Maria Van Kerkhove was quick to calibrate expectations: "This is not the next COVID, but it is a serious infectious disease" [4]. The CDC echoed that assessment, stating the threat of a widespread outbreak remained low [5]. Yet the episode exposed a more uncomfortable truth: more than three decades after hantavirus pulmonary syndrome (HPS) was first identified in the American Southwest, there is still no licensed vaccine or specific antiviral treatment available anywhere outside East Asia [6].

The Outbreak: What Happened on the Hondius

The index patient, a Dutch citizen, had spent four months traveling through Chile, Uruguay, and Argentina before boarding the ship on April 1, 2026. Health officials believe he and his wife contracted the Andes virus during a birdwatching excursion near a landfill in Ushuaia [2]. He died aboard the ship on April 11; his wife was evacuated to a hospital in Johannesburg via Saint Helena, where she also died [2]. A third passenger subsequently died on board.

The Andes virus is the only hantavirus known to transmit between humans, though such transmission requires close, sustained contact [7]. Spread aboard the Hondius has been attributed at least in part to person-to-person transmission — an unusual event that elevated concern beyond the typical rodent-to-human exposure pathway [2][4].

South African health officials traced 62 potential contacts of the disembarked passenger; 42 tested negative [4]. As of May 8, passengers were hospitalized in South Africa, the Netherlands, Germany, Saint Helena, Spain, and Switzerland [2][3].

A Disease That Kills One in Three — and Gets Almost No Funding

Hantavirus pulmonary syndrome carries a case fatality rate of approximately 35 percent in the United States, based on 890 confirmed cases reported between 1993 and 2023 [8]. In South America, where the Andes virus predominates, fatality rates range from 20 to 50 percent depending on the region and the viral strain [6]. The WHO estimates that 10,000 to over 100,000 hantavirus infections occur globally each year, with the largest burden in Asia and Europe, where the disease typically manifests as hemorrhagic fever with renal syndrome (HFRS) rather than the more lethal pulmonary form [6].

In the Americas, the numbers are smaller but the mortality is stark. In 2025, PAHO reported 229 confirmed cases and 59 deaths across eight countries — a case fatality rate of nearly 26 percent [9]. Argentina led with 66 cases and 21 deaths. The current Argentine season, which began in June 2025, has already recorded 101 confirmed cases, nearly double the 57 reported during the same period the prior year [10].

Source: PAHO Epidemiological Alert

Data as of Dec 19, 2025CSV

In the United States, the disease is rare but persistent. The CDC has documented 890 laboratory-confirmed cases since 1993, with 94 percent occurring west of the Mississippi River. The demographic profile skews male (62 percent) and disproportionately affects American Indian and Alaska Native populations, who account for 19 percent of cases despite representing roughly 2 percent of the U.S. population [8].

The low absolute case count is precisely what has starved hantavirus research of investment. Sabra Klein, a professor at the Johns Hopkins Bloomberg School of Public Health, put it bluntly: "Our funding agencies don't put a lot of money into this, because it's likely not to cause the next epidemic or pandemic" [11].

The Vaccine Pipeline: Promising Science, Distant Timelines

Several hantavirus vaccine candidates exist in various stages of development, but none in the Western Hemisphere has advanced beyond Phase 1 clinical trials.

DNA vaccines (USAMRIID). The U.S. Army Medical Research Institute of Infectious Diseases has led the most advanced Western vaccine program. A Phase 1 trial of an Andes virus DNA vaccine, published in the Journal of Infectious Diseases in 2024, enrolled 48 healthy adults and used needle-free jet injection across three- and four-dose schedules. The vaccine was well-tolerated, and 98 percent of recipients experienced at least one local adverse event (mostly mild injection-site reactions), but it induced "robust and durable" neutralizing antibody responses [12]. A separate Phase 1 trial tested DNA vaccines targeting the Hantaan and Puumala strains, with similar safety and immunogenicity results [13].

mRNA vaccines (Moderna/Korea University). Moderna and Korea University's Vaccine Innovation Center have collaborated since September 2023 through Moderna's mRNA Access Program. Korea University provided antigen sequences; Moderna supplied mRNA constructs. In February 2025, Professor Park Man-sung's team confirmed that experimental doses prevented hantavirus infection in mice [14]. The work targets HFRS-causing strains prevalent in East Asia and remains preclinical.

Ensilication technology (EnsiliTech). The U.K.-based biotech EnsiliTech has developed an mRNA vaccine candidate using a proprietary silica-cage technology that allows room-temperature storage — a significant advantage for distribution in remote areas. Co-founder Matt Slade told NBC News his team began work 15 years ago. Rodent trials have been completed, but early-stage human clinical trials are an estimated three to four years away [11].

Recombinant viral vector (University of Marburg). A 2025 study published in Vaccines described a multi-valent hantavirus vaccine based on modified vaccinia Ankara (MVA) that reduced viral load in a mouse infection model [15].

Traws Pharma. In May 2026, Traws Pharma announced plans to advance clinical candidates for hantavirus treatment — an antiviral rather than vaccine approach [16].

Without an accelerated federal program analogous to Operation Warp Speed, experts estimate it will take at least five more years to complete Phase 2 and 3 trials for any of these candidates [11]. Prediction markets reflect this assessment: Polymarket and Kalshi placed the probability of a licensed hantavirus vaccine by the end of 2026 at essentially zero [17].

Source: OpenAlex

Data as of Jan 1, 2026CSV

South Korea's Hantavax: A Cautionary Precedent

South Korea licensed Hantavax, an inactivated vaccine derived from rodent brain tissue, decades ago. It remains the only hantavirus vaccine in wide use outside China. But the peer-reviewed evidence on its efficacy has been consistently equivocal.

A field study found that protective effectiveness increased with the number of doses — 25 percent for one dose, 46 percent for two, and 75 percent for three — but all 95 percent confidence intervals overlapped zero, meaning the results could be attributable to chance [18]. Following two primary doses, seroconversion rates for neutralizing antibodies were just 33 percent [19]. More recent Phase 3 data showed improved immunogenicity: three primary doses yielded an 81 percent seroconversion rate by neutralization assay, and booster doses raised seropositive rates further [20].

Researchers have called for well-designed field trials and greater investigation of cell-mediated immunity, not just antibody responses [19]. The vaccine has not been adopted outside South Korea and China in part because of manufacturing limitations (it relies on rodent brain-derived antigen), uncertain efficacy, and the lack of commercial interest from multinational pharmaceutical companies in pursuing international licensure for a disease with low global incidence [11][18].

The Hantavax story illustrates a recurring pattern in neglected disease vaccine development: a product can exist and even be licensed in one country without ever reaching the populations elsewhere that need it most.

Why Neglect Persists: The Economics of Sporadic Disease

Hantavirus occupies an uncomfortable position in the global health landscape. Its case fatality rate for the pulmonary form rivals or exceeds that of Ebola in some outbreaks, yet its absolute case numbers are orders of magnitude smaller. This creates a structural disincentive for commercial vaccine development.

"There has to be a strong commercial case for these vaccines," one researcher told Nature. "Hantaviruses tend to be endemic in parts of the world that don't really have that financial backing, so there's been a lack of interest" [11]. EnsiliTech's Slade noted he was drawn to the project partly because "we looked at hantavirus and saw it was pretty neglected. There wasn't really any work in the sector" [11].

Federal funding has been limited and, more recently, reduced. The NIH's National Institute of Allergy and Infectious Diseases (NIAID) had allocated more than $8.3 million to the West African Center for Emerging Infectious Diseases (WAC-EID) through the Centers for Research in Emerging Infectious Diseases (CREID) network. Approximately $100,000 of that total supported a pilot project in Argentina studying how hantavirus passes from rodents to humans. In 2025, the Trump administration eliminated funding for the entire CREID network — 10 centers in total — with nearly $2.4 million in WAC-EID funds left undisbursed [21].

The opportunity-cost argument deserves a fair hearing. Some epidemiologists who track neglected tropical diseases argue that emergency funding surges toward low-incidence outbreaks can divert resources from higher-burden diseases that lack media attention. Tuberculosis kills roughly 1.3 million people annually; Chagas disease affects an estimated 6-7 million. When a single cruise ship outbreak dominates news cycles, the resulting political pressure to redirect funds can come at the expense of diseases with far greater cumulative mortality but no viral news hook [6]. The CDC's own assessment — that widespread hantavirus transmission remains unlikely — lends weight to this position [5].

Who Bears the Risk: Occupation, Geography, and Structural Vulnerability

The populations most exposed to hantavirus are not cruise ship tourists but rural workers, indigenous communities, and low-income residents of areas where human activity intersects with rodent habitats.

CDC data from 1993 to 2015 identified agriculture, construction, and forestry/outdoor recreation as the occupations most associated with hantavirus exposure in the United States [22]. Seroprevalence studies — measuring past infection through antibody detection — consistently show higher rates in occupations and regions with greater rodent exposure [22]. In South America, outdoor rural work, recreational activities in forested areas, and habitation in non-ventilated buildings are established risk factors [23].

American Indian and Alaska Native populations face a dramatically disproportionate burden. They represent 19 percent of confirmed U.S. hantavirus cases despite comprising roughly 2 percent of the national population [8]. The disease was first identified during a 1993 outbreak in the Navajo Nation, and the Four Corners region of Arizona, Colorado, New Mexico, and Utah remains a persistent hotspot.

Climate and land-use changes are accelerating risk. In Argentina, where hantavirus cases nearly doubled between the 2024 and 2025 seasons, experts point to extreme weather — alternating droughts and heavy rainfall — that disrupts rodent population cycles and drives the long-tailed pygmy rice mouse (Oligoryzomys longicaudatus), the primary Andes virus reservoir, into closer contact with humans [10]. The expansion of the soybean agricultural frontier since the 2000s has driven deforestation in endemic regions, and a 2020 study in PLOS Neglected Tropical Diseases linked HPS outbreaks in northwestern Argentina to specific climate variables over a 20-year period [23][24].

The Last-Mile Problem: Delivering a Vaccine That Doesn't Yet Exist

Even if a hantavirus vaccine reaches approval within the next five to ten years, distribution to the highest-risk populations presents formidable challenges. The communities most affected — rural agricultural workers in Patagonia, indigenous populations in the American Southwest, subsistence farmers in Bolivia and Paraguay — often lack reliable cold-chain infrastructure, consistent access to primary care, and the multi-visit schedules that current vaccine candidates require (three to four doses over several months) [12][13].

EnsiliTech's ensilication technology, which eliminates the need for cold storage, represents one attempt to solve the cold-chain problem [11]. Single-dose or two-dose formulations would further reduce barriers, but no candidate has yet demonstrated adequate protection without at least three injections.

Historical precedent for vaccinating remote populations against rodent-borne zoonotic diseases is thin. The closest analogue may be China's experience with inactivated hantavirus vaccines, where roughly two million doses were administered annually, contributing to a decline in HFRS cases from over 100,000 per year to fewer than 20,000 by 2007 [6]. But China's campaign relied on state-directed public health infrastructure operating at a scale that has no parallel in the fragmented health systems of rural South America or the underfunded Indian Health Service in the United States.

Source: OpenAlex

Data as of Jan 1, 2026CSV

What Comes After the Headlines

Academic publication data reveals a pattern: hantavirus research surges during outbreaks and recedes when attention fades. The OpenAlex database shows 11,602 papers published on hantavirus since 2011, peaking at 1,148 in 2023. Vaccine-specific publications peaked at 457 that same year [25]. Whether the Hondius outbreak generates sustained investment or merely a temporary spike remains an open question.

Ofer Levy, director of the Precision Vaccines Program at Boston Children's Hospital, has argued that the mRNA platform's flexibility could reduce the cost and timeline of hantavirus vaccine development relative to older technologies [11]. The infrastructure built during the COVID-19 pandemic — manufacturing capacity, regulatory pathways for emergency use authorization, global distribution networks — could theoretically be repurposed. But "could" and "will" are separated by the same gap that has kept hantavirus in the neglected-disease category for 30 years: commercial demand.

The three passengers who died aboard the MV Hondius contracted a virus for which treatment consists of supportive care — oxygen, fluids, mechanical ventilation if needed — and nothing more [6]. The science to change that exists in laboratories in Maryland, Cambridge, Seoul, and Bath. The funding, political will, and market incentives to move it from bench to bedside do not yet match the urgency of the pathogen itself.